Lunai Bioworks Inc.
RENBNASDAQHealthcare
$1.42
+$0.00(+0.00%)
Market Cap$32915951
P/E Ratio—
52W High$21
52W Low$1.1208
Lunai Bioworks Inc. (RENB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RENB · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 17, 2026EPS Actual
-$0.08
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 17, 2026
After Market Close
RENB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 17, 2026 | — | -$0.08 | — | — | — | — |
| — Q4 FY2025 | Nov 13, 2025 | — | $0.13 | — | — | — | — |
| — Q3 FY2025 | Sep 29, 2025 | — | -$0.77 | — | $0.00B | — | — |
| — Q2 FY2025 | May 15, 2025 | — | $0.01 | — | — | — | — |
| — Q1 FY2025 | Feb 19, 2025 | — | -$0.02 | — | — | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$0.03 | — | — | — | — |
| — Q4 FY2024 | Oct 10, 2024 | — | -$0.45 | — | $0.00B | — | — |
| — Q3 FY2024 | Jul 19, 2024 | — | -$1.58 | — | — | — | — |
Q1 FY2026
Feb 17, 2026
EPS Actual
-$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 13, 2025
EPS Actual
$0.13
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 29, 2025
EPS Actual
-$0.77
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 19, 2025
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 14, 2024
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Oct 10, 2024
EPS Actual
-$0.45
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Jul 19, 2024
EPS Actual
-$1.58
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $1.52 | $1.52 | $1.52 | 1 |
| Q2 FY2025 | $1.32 | $1.32 | $1.32 | 1 |
| Q1 FY2025 | $1.55 | $1.55 | $1.55 | 1 |
| Q3 FY2024 | $1.52 | $1.52 | $1.52 | 1 |
| Q2 FY2024 | $1.32 | $1.32 | $1.32 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 17, 2026 | — | $1.05 | — | — |
| — Q4 FY2025 | Nov 13, 2025 | — | $1.05 | — | — |
| — Q3 FY2025 | Sep 29, 2025 | — | $1.30 | $1.27 | -2.31% |
| — Q2 FY2025 | May 15, 2025 | — | $3.30 | $3.33 | +0.91% |
| — Q1 FY2025 | Feb 19, 2025 | — | $8.14 | $8.60 | +5.65% |
| — Q4 FY2024 | Nov 14, 2024 | — | $6.02 | $5.84 | -2.99% |
| — Q4 FY2024 | Oct 10, 2024 | — | $4.20 | $4.40 | +4.76% |
| — Q3 FY2024 | Jul 19, 2024 | — | $14.00 | $13.50 | -3.57% |
Q1 FY2026—
Report Date
Feb 17, 2026
EPS Beat/Miss
—
Price Before
$1.05
Price After
—
Q4 FY2025—
Report Date
Nov 13, 2025
EPS Beat/Miss
—
Price Before
$1.05
Price After
—
Q3 FY2025-2.31%
Report Date
Sep 29, 2025
EPS Beat/Miss
—
Price Before
$1.30
Price After
$1.27
Q2 FY2025+0.91%
Report Date
May 15, 2025
EPS Beat/Miss
—
Price Before
$3.30
Price After
$3.33
Q1 FY2025+5.65%
Report Date
Feb 19, 2025
EPS Beat/Miss
—
Price Before
$8.14
Price After
$8.60
Q4 FY2024-2.99%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$6.02
Price After
$5.84
Q4 FY2024+4.76%
Report Date
Oct 10, 2024
EPS Beat/Miss
—
Price Before
$4.20
Price After
$4.40
Q3 FY2024-3.57%
Report Date
Jul 19, 2024
EPS Beat/Miss
—
Price Before
$14.00
Price After
$13.50
Beat Rate0 / 8 quarters
Largest Move+5.65% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RENB ends December
Lunai Bioworks Inc. (RENB) most recently reported earnings on February 17, 2026 for Q1 FY2026, posting EPS of $-0.08 (in line with the analyst consensus of —). The next RENB earnings date is expected around September 1, 2026.
Each quarter, investors track RENB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RENB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RENB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RENB earnings · 4 questionsLunai Bioworks Inc.'s next earnings report is expected around September 1, 2026. RENB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RENB historically reports after market close (AMC).
RENB earnings datewhen is RENB earningsRENB next earnings datewhen does RENB report earningsRENB earnings calendar
▸ Source: FMP · Lunai Bioworks Inc. SEC filings · US GAAP · Lunai Bioworks Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026